A targeted, low-throughput compound screen in a Drosophila model of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD) (2022)
Attributed to:
Homeostatic control of neuron excitability
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2022.11.11.516139
Publication URI: http://dx.doi.org/10.1101/2022.11.11.516139
Type: Preprint